Patents Assigned to Pfizer Products Inc.
  • Patent number: 8999981
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: April 7, 2015
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • Publication number: 20120142749
    Abstract: The present invention relates to solid salt forms of the 3-pyrrole substituted 2-indolinone compound 5-[5-fluoro-2-oxo-1, 2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pirrolidin-1-yl-ethyl)-amide. It also relates to polymorphs of the phosphate salt of the amide. The invention further relates to the use of the salts and polymorphs in the treatment of protein kinase related disorders.
    Type: Application
    Filed: February 6, 2012
    Publication date: June 7, 2012
    Applicants: PFIZER PRODUCTS INC., PFIZER INC.
    Inventors: Changquan C. Sun, Michael Hawley
  • Patent number: 8183230
    Abstract: The present invention is directed to pharmaceutical compositions containing a therapeutically effective amount of an Active Pharmaceutical Ingredient (“API”), a pharmaceutically acceptable cyclodextrin and a pharmaceutically acceptable preservative. The invention is also directed to pharmaceutical compositions of the compounds of Formula (I) wherein R2 is selected from the group consisting of methyl, ethyl, isopropyl, sec-butyl and tert-butyl and a pharmaceutically acceptable cyclodextrin and preservative. Formula (I): In particular, the invention is directed to pharmaceutical compositions of the compound of Formula 1a, and a pharmaceutically acceptable cyclodextrin and a preservative.
    Type: Grant
    Filed: January 17, 2005
    Date of Patent: May 22, 2012
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Roger C. Adami, Frederick David, Julia Ann Wood
  • Patent number: 8114871
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts of Formula (I): wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications (including in particular diabetic retinopathy, nephropathy or neuropathy), cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease and dermatological disease pression, viral diseases, inflammatory disorders, or diseases in which the liver is a target organ.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: February 14, 2012
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Iriny Botrous, Yufeng Hong, Hui Li, Kevin Kun-Chin Liu, Seiji Nukui, Min Teng, Eileen Valenzuela Tompkins, Chunfeng Yin
  • Patent number: 8008078
    Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: August 30, 2011
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Kim J. Stutzman-Engwall, Anke Krebber, Claes Gustafsson, Jeremy S. Minshull, Sun Ai Raillard, Seran Kim, Yan Chen
  • Patent number: 7968584
    Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: June 28, 2011
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
  • Publication number: 20110046385
    Abstract: The present invention relates to polymorphic crystalline forms or a non-crystalline form or amorphous of the compound (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof together with processes for preparing, methods for using, and pharmaceutical compositions containing the same. The invention also relates to substantially pure polymorphic crystalline forms or a non-crystalline form or amorphous form of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof.
    Type: Application
    Filed: August 25, 2008
    Publication date: February 24, 2011
    Applicant: PFIZER PRODUCTS INC.
    Inventors: David B. Damon, Jinyang Hong, Joseph F. Krzyzaniak
  • Patent number: 7858340
    Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: December 28, 2010
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Kim J. Stutzman-Engwall, Yan Chen, Claes Gustafsson, Anke Krebber, Jeremy Minshull, Sun Ai Raillard
  • Patent number: 7820648
    Abstract: The present invention relates to a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula and R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, salt thereof, wherein R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: October 26, 2010
    Assignees: Pfizer Inc, Pfizer Products Inc
    Inventors: Samit Kumar Bhattacharya, Michael Joseph Luzzio, Donn Gregory Wishka, Gonghua Pan, Arthur Douglas Brosius, Joel Thomas Arcari, James Alfred Southers, Jr., Kendra Louise Nelson, Jun Xiao
  • Patent number: 7803832
    Abstract: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: September 28, 2010
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Douglas James Critcher, Nigel Derek Arthur Walshe, Christelle Lauret
  • Publication number: 20100222353
    Abstract: The invention pertains to new aminophthalazine compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.
    Type: Application
    Filed: January 22, 2007
    Publication date: September 2, 2010
    Applicant: PFIZER PRODUCTS INC.
    Inventor: John Michael Humphrey
  • Publication number: 20100197624
    Abstract: A method is provided for the treatment of parasitic infestations in mammals, comprising the step of simultaneously or sequentially administering to the mammal effective amounts of (a) 2-desoxoparaherquamide; and (b) abamectin. Also provided is an anthelmintic composition comprising 2-desoxoparaherquamide and abamectin.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 5, 2010
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Timothy G. Geary, Peter Rolfe
  • Publication number: 20100168410
    Abstract: A composition for manufacture of hard hydroxypropyl methyl cellulose capsules comprising a film forming material of hydroxypropyl methyl cellulose having a methoxy content of 27.0-30.0% (w/w), and a hydroxypropoxy content of 4.0-7.5% and as a 2% weight solution, a viscosity of 3.5-6.0 cPs at 20° C., dipping compositions, process for manufacture of hard hydroxypropyl methyl cellulose capsules according to a dip coating process and hard capsule shells.
    Type: Application
    Filed: October 17, 2007
    Publication date: July 1, 2010
    Applicant: PFIZER PRODUCTS INC.
    Inventors: Dominique Nicolas Cade, David He Xinwe
  • Patent number: 7687507
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: March 30, 2010
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown
  • Patent number: 7687533
    Abstract: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: March 30, 2010
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Douglas James Critcher, Nigel Derek Arthur Walshe, Christelle Lauret
  • Publication number: 20100075956
    Abstract: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    Type: Application
    Filed: December 1, 2009
    Publication date: March 25, 2010
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Douglas James Critcher, Nigel Derek Arthur Walshe, Christelle Lauret
  • Publication number: 20100056571
    Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Application
    Filed: November 12, 2009
    Publication date: March 4, 2010
    Applicants: Pfizer Inc., Pfizer Products Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Publication number: 20100056506
    Abstract: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    Type: Application
    Filed: April 19, 2007
    Publication date: March 4, 2010
    Applicant: PFIZER PRODUCTS INC.
    Inventors: Liming Huang, Song Liu, Elizabeth A. Lunney, Simon P. Planken
  • Publication number: 20100029710
    Abstract: Compounds of following formula (I) are provided that have both angiotensin II receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the compounds including type 2 diabetes, insulin resistance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, metabolic syndrome, congestive heart failure, and hypertension.
    Type: Application
    Filed: December 3, 2007
    Publication date: February 4, 2010
    Applicant: Pfizer Products Inc.
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Chitase Lee, Hud Lawrence Risley, Robert Philip Schaum
  • Publication number: 20100028379
    Abstract: This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
    Type: Application
    Filed: November 23, 2007
    Publication date: February 4, 2010
    Applicants: PFIZER, INC, PFIZER PRODUCTS INC.
    Inventors: Cassius M. Tucker, John David Haworth